Relmada Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
NDV-01, an extended-release gemcitabine/docetaxel, showed strong phase II results and is advancing to phase III in both high-risk and intermediate-risk bladder cancer. A pre-filled syringe formulation aims to expand use beyond academia, with robust IP and financial runway through 2029.
-
The meeting saw approval of all proposals, including director elections and amendments to the equity plan and articles. Strategic acquisitions and disciplined management led to a sharp rise in share price and market capitalization, positioning the company for future growth.
-
Robust 12-month phase II data for NDV-01 in NMIBC, strong cash position after $160M financing, and phase III RESCUE program set to launch mid-2026. Patent filings may extend exclusivity to 2047, and cash runway is projected through 2029.
-
NDV-01, a sustained-release Gem/Doce gel for bladder cancer, shows high 12-month CR rates and favorable safety, with pivotal trials starting mid-year. The company raised $160 million to support development, aiming for broad adoption in both high- and intermediate-risk settings.
Fiscal Year 2025
-
2025 saw major clinical and financial milestones, including strong NDV-01 phase II data, FDA alignment for phase III, and a $160M financing extending runway through 2029. NDV-01's efficacy and safety profile position it as a potential best-in-class NMIBC therapy.
-
Strong nine-month phase II data for NDV-01 in NMIBC and FDA alignment on phase III program de-risk the pipeline. Financial position strengthened by a $100 million capital raise, supporting operations and clinical trials into 2028.
-
A new extended-release chemotherapy gel for bladder cancer shows 90% cancer-free rates at six months, aiming to offer a more convenient and cost-effective alternative to current high-priced treatments. Financials remain solid, with additional funding anticipated to support clinical milestones.
-
Six-month phase II data for NDB01 in high-risk NMIBC showed a 91% response rate and strong safety, while Sepranolone advances toward a phase II study in Prader-Willi syndrome. Cash balance stands at $20.6 million, with reduced R&D spend ahead of new trial initiations.
-
Two new product candidates with positive phase II data were added, including NDV-01 for bladder cancer, which showed high response rates and strong safety, and sepranolone for neurobehavioral disorders. Cash balance was $27.1 million, with reduced expenses and a focus on advancing both programs to key milestones.
-
NDV-01, a novel intravesical gemcitabine/docetaxel therapy for high-risk NMIBC, showed 85–90% high-grade recurrence-free survival and 100% complete response in CIS patients at three months, with minimal side effects and improved quality of life. Its ready-to-use format offers significant advantages for community urologists, and further clinical updates and regulatory steps are planned.
Fiscal Year 2024
-
Prioritized pipeline and resource allocation led to acquisition of NDV-01 and sepranolone, with both programs advancing toward key clinical milestones. Operating expenses and net loss decreased year-over-year, and cash reserves stand at $44.9M as of year-end 2024.
-
Relmada 1017 is in late-stage trials for adjunctive MDD, with interim data expected soon and significant protocol improvements to address past challenges. Financials are strong, and a new psilocybin analog program is advancing, with early data expected next quarter.
-
Advancement of CNS disorder treatments continues, with a key phase III interim analysis for Relmada 1017 expected by year-end 2024. Cash reserves support operations into 2025, and a new psilocybin-based program is entering clinical trials.
-
Advanced Phase III trials for REL-1017 in depression with key milestones expected by year-end 2024. Q2 net loss narrowed to $17.8M, and cash reserves of $70.4M are expected to fund operations into 2025.
-
The Relight trial for adjunctive MDD features a simplified protocol, enhanced site and patient selection, and stricter criteria to control placebo response. REL-1017 is positioned for rapid onset, strong tolerability, and low abuse potential, with pivotal data expected this year.
-
REL-1017, an oral NMDA antagonist for adjunctive depression treatment, is in late-stage development with improved phase III trial protocols and rigorous patient selection. Data from the first phase III trial is expected in the second half of this year, with strong safety, efficacy, and financial runway through 2025.